What is Taysha Gene Therapies, Inc.'s earnings per share (EPS)?

Taysha Gene Therapies, Inc. (TSHA) reported diluted earnings per share of $-0.34 for fiscal year 2025. This represents a 5.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Taysha Gene Therapies, Inc. Financials

TSHA

Source SEC Filings (10-K/10-Q) Updated Mar 19, 2026 Currency USD FYE March

This page shows Taysha Gene Therapies, Inc. (TSHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, Taysha Gene Therapies, Inc. generates $0.85 in operating cash flow (-$93.1M OCF vs -$109.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1753.9x

Taysha Gene Therapies, Inc. earns $-1753.9 in operating income for every $1 of interest expense (-$110.5M vs $63K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.8M

YoY+17.3%

Taysha Gene Therapies, Inc. generated $9.8M in revenue in fiscal year 2025. This represents an increase of 17.3% from the prior year.

EBITDA

-$109.4M

YoY-21.2%

Taysha Gene Therapies, Inc.'s EBITDA was -$109.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.2% from the prior year.

Net Income

-$109.0M

YoY-22.1%

Taysha Gene Therapies, Inc. reported -$109.0M in net income in fiscal year 2025. This represents a decrease of 22.1% from the prior year.

EPS (Diluted)

$-0.34

YoY+5.6%

Taysha Gene Therapies, Inc. earned $-0.34 per diluted share (EPS) in fiscal year 2025. This represents an increase of 5.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$93.8M

YoY-15.0%

Taysha Gene Therapies, Inc. generated -$93.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 15.0% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

287M

YoY+40.2%

5Y CAGR+50.1%

Taysha Gene Therapies, Inc. had 287M shares outstanding in fiscal year 2025. This represents an increase of 40.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-1130.7%

YoY-33.1pp

Taysha Gene Therapies, Inc.'s operating margin was -1130.7% in fiscal year 2025, reflecting core business profitability. This is down 33.1 percentage points from the prior year.

Net Margin

-1115.3%

YoY-43.6pp

Taysha Gene Therapies, Inc.'s net profit margin was -1115.3% in fiscal year 2025, showing the share of revenue converted to profit. This is down 43.6 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$86.4M

YoY+30.9%

5Y CAGR+22.1%

Taysha Gene Therapies, Inc. invested $86.4M in research and development in fiscal year 2025. This represents an increase of 30.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$738K

YoY+97.3%

5Y CAGR+55.2%

Taysha Gene Therapies, Inc. invested $738K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 97.3% from the prior year.

TSHA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$9.8M+17.3%	$8.3M-46.1%	$15.5M+517.5%	$2.5M	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$86.4M+30.9%	$66.0M+16.2%	$56.8M-37.7%	$91.2M-30.9%	$131.9M+313.7%	$31.9M
SG&A Expenses	$33.9M+17.0%	$29.0M-3.6%	$30.0M-19.6%	$37.4M-9.6%	$41.3M+272.0%	$11.1M
Operating Income	-$110.5M-20.8%	-$91.5M-26.3%	-$72.4M+55.4%	-$162.4M+6.2%	-$173.3M-302.9%	-$43.0M
Interest Expense	$63K-38.2%	$102K-98.0%	$5.0M+31.6%	$3.8M+166.0%	$1.4M+5000.0%	$28K
Income Tax	N/A	$0	$0	$0	N/A	$0
Net Income	-$109.0M-22.1%	-$89.3M+20.0%	-$111.6M+32.8%	-$166.0M+4.9%	-$174.5M-190.8%	-$60.0M
EPS (Diluted)	$-0.34+5.6%	$-0.36+62.5%	$-0.96+74.6%	$-3.78+18.5%	$-4.64	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$0-100.0%	$2.0M-13.7%	$2.3M+13.8%	$2.0M+13.1%	$1.8M+60.8%	$1.1M-67.4%	$3.4M-5.4%	$3.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$25.7M+27.8%	$20.1M+29.4%	$15.6M+1.6%	$15.3M+2.5%	$14.9M-0.8%	$15.1M-27.0%	$20.7M+62.9%	$12.7M
SG&A Expenses	$8.3M-3.7%	$8.6M+5.4%	$8.2M+23.1%	$6.6M-16.1%	$7.9M+7.7%	$7.3M+3.6%	$7.1M+5.4%	$6.7M
Operating Income	-$34.0M-27.2%	-$26.8M-24.9%	-$21.4M-7.5%	-$19.9M+23.0%	-$25.9M-21.6%	-$21.3M+12.5%	-$24.3M-49.8%	-$16.2M
Interest Expense	$15K-11.8%	$17K-10.5%	$19K-13.6%	$22K-8.3%	$24K-11.1%	$27K-6.9%	$29K-95.9%	$713K
Income Tax	N/A	N/A	$0	N/A	N/A	N/A	$0	N/A
Net Income	-$32.7M-21.8%	-$26.9M-24.9%	-$21.5M-14.6%	-$18.8M+26.4%	-$25.5M-22.0%	-$20.9M+13.0%	-$24.1M-150.4%	$47.7M
EPS (Diluted)	$-0.090.0%	$-0.09-12.5%	$-0.08	N/A	$-0.10-11.1%	$-0.09+10.0%	$-0.10	N/A

TSHA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$160.4M-7.2%	$172.7M+36.8%	$126.3M-41.0%	$214.0M-17.4%	$258.9M
Current Assets	N/A	$142.1M-5.2%	$149.9M+55.4%	$96.4M-39.6%	$159.6M-38.1%	$257.9M
Cash & Equivalents	N/A	$139.0M-3.4%	$143.9M+63.8%	$87.9M-41.1%	$149.1M-40.7%	$251.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$88.8M-9.2%	$97.8M-22.0%	$125.3M+5.7%	$118.6M+1464.5%	$7.6M
Current Liabilities	N/A	$26.2M-28.6%	$36.8M-41.5%	$62.8M+21.3%	$51.7M+625.9%	$7.1M
Long-Term Debt	N/A	$43.9M+8.5%	$40.5M+6.7%	$38.0M+2.1%	$37.2M	N/A
Total Equity	N/A	$71.5M-4.6%	$74.9M+7796.4%	$949K-99.0%	$95.4M-62.0%	$251.3M
Retained Earnings	N/A	-$602.3M-17.4%	-$513.0M-27.8%	-$401.4M-70.4%	-$235.6M-285.5%	-$61.1M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$316.6M-5.0%	$333.3M+140.9%	$138.4M-13.7%	$160.4M-11.0%	$180.2M-10.1%	$200.4M+31.0%	$153.0M-11.4%	$172.7M
Current Assets	$300.0M-5.2%	$316.3M+162.0%	$120.7M-15.1%	$142.1M-12.0%	$161.6M-9.5%	$178.5M+36.7%	$130.6M-12.9%	$149.9M
Cash & Equivalents	$297.3M-4.9%	$312.8M+168.3%	$116.6M-16.1%	$139.0M-11.8%	$157.7M-8.7%	$172.7M+39.3%	$124.0M-13.9%	$143.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$97.6M+15.3%	$84.6M+1.6%	$83.3M-6.2%	$88.8M-2.8%	$91.4M-0.1%	$91.5M-7.7%	$99.2M+1.4%	$97.8M
Current Liabilities	$28.6M+12.9%	$25.3M+12.4%	$22.6M-14.0%	$26.2M-10.6%	$29.3M-14.2%	$34.2M-11.5%	$38.6M+5.1%	$36.8M
Long-Term Debt	$50.9M+23.9%	$41.1M-3.3%	$42.5M-3.4%	$43.9M+2.3%	$43.0M+13.6%	$37.8M-6.6%	$40.5M0.0%	$40.5M
Total Equity	$219.0M-12.0%	$248.7M+351.7%	$55.1M-23.0%	$71.5M-19.5%	$88.8M-18.4%	$108.9M+102.2%	$53.8M-28.1%	$74.9M
Retained Earnings	-$683.4M-5.0%	-$650.7M-4.3%	-$623.8M-3.6%	-$602.3M-3.2%	-$583.5M-4.6%	-$558.0M-3.9%	-$537.1M-4.7%	-$513.0M

TSHA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$93.1M-14.6%	-$81.2M-11.2%	-$73.0M+17.4%	-$88.4M+24.5%	-$117.0M-280.9%	-$30.7M
Capital Expenditures	$738K+97.3%	$374K-90.3%	$3.9M-81.2%	$20.6M+34.7%	$15.3M+18563.4%	$82K
Free Cash Flow	-$93.8M-15.0%	-$81.6M-6.1%	-$76.9M+29.5%	-$109.0M+17.6%	-$132.3M-329.5%	-$30.8M
Investing Cash Flow	-$604K-66.4%	-$363K+95.1%	-$7.4M+70.5%	-$24.9M-15.7%	-$21.6M-137.3%	-$9.1M
Financing Cash Flow	$274.6M+258.1%	$76.7M-43.8%	$136.4M+161.8%	$52.1M+33.3%	$39.1M-86.6%	$291.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$24.2M-19.7%	-$20.2M+8.3%	-$22.0M-20.3%	-$18.3M+15.3%	-$21.6M-0.5%	-$21.5M-8.6%	-$19.8M-22.8%	-$16.1M
Capital Expenditures	$108K	N/A	N/A	-$2K-105.7%	$35K-82.6%	$201K+43.6%	$140K+723.5%	$17K
Free Cash Flow	-$24.3M	N/A	N/A	-$18.3M+15.4%	-$21.6M+0.3%	-$21.7M-8.9%	-$19.9M-23.6%	-$16.1M
Investing Cash Flow	-$48K-177.4%	$62K+116.7%	-$371K-2953.8%	$13K+137.1%	-$35K+82.6%	-$201K-43.6%	-$140K-1300.0%	-$10K
Financing Cash Flow	$8.8M-95.9%	$216.3M+416038.5%	-$52K+85.4%	-$357K-105.4%	$6.6M-90.6%	$70.5M+320409.1%	-$22K+99.5%	-$4.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TSHA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1130.7%-33.1pp	-1097.5%-628.7pp	-468.8%+6023.9pp	-6492.7%	N/A	N/A
Net Margin	-1115.3%-43.6pp	-1071.6%-349.6pp	-722.1%+5913.2pp	-6635.3%	N/A	N/A
Return on Equity	N/A	-124.8%+24.0pp	-148.9%+17344.7pp	-17493.6%-17310.6pp	-183.0%-159.1pp	-23.9%
Return on Assets	N/A	-55.7%+8.9pp	-64.6%+66.9pp	-131.5%-49.9pp	-81.6%-58.4pp	-23.2%
Current Ratio	N/A	5.42+1.3	4.08+2.5	1.54-1.5	3.08-33.1	36.17
Debt-to-Equity	N/A	0.61+0.1	0.54-39.5	40.01+39.6	0.39+0.4	0.03
FCF Margin	-960.1%+19.2pp	-979.2%-481.6pp	-497.6%+3859.3pp	-4356.9%	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-1347.1%-416.5pp	-930.5%+55.2pp	-985.8%+462.7pp	-1448.4%+467.0pp	-1915.4%-1202.1pp	-713.3%-262.5pp	-450.8%
Net Margin	N/A	-1353.6%-418.4pp	-935.2%-6.2pp	-929.0%+498.5pp	-1427.5%+454.5pp	-1882.0%-1176.6pp	-705.4%-2030.1pp	1324.7%
Return on Equity	-14.9%-4.1pp	-10.8%+28.3pp	-39.1%-12.8pp	-26.3%+2.5pp	-28.7%-9.5pp	-19.2%+25.5pp	-44.7%-108.4pp	63.7%
Return on Assets	-10.3%-2.3pp	-8.1%+7.5pp	-15.6%-3.8pp	-11.7%+2.5pp	-14.2%-3.7pp	-10.4%+5.3pp	-15.7%-43.4pp	27.6%
Current Ratio	10.48-2.0	12.48+7.1	5.35-0.1	5.42-0.1	5.51+0.3	5.22+1.8	3.38-0.7	4.08
Debt-to-Equity	0.23+0.1	0.17-0.6	0.77+0.2	0.61+0.1	0.48+0.1	0.35-0.4	0.75+0.2	0.54
FCF Margin	N/A	N/A	N/A	-905.5%+305.3pp	-1210.8%+741.0pp	-1951.9%-1367.4pp	-584.5%-136.8pp	-447.7%

Similar Companies

Uniqure QURE

$1.0B

Oculis Holding OCS

$1.5B

Sana Biotechnology, Inc. SANA

$768.6M

UpStream Bio Inc. UPB

$489.8M

EyePoint EYPT

$1.1B

Frequently Asked Questions

What is Taysha Gene Therapies, Inc.'s annual revenue?

Taysha Gene Therapies, Inc. (TSHA) reported $9.8M in total revenue for fiscal year 2025. This represents a 17.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Taysha Gene Therapies, Inc.'s revenue growing?

Taysha Gene Therapies, Inc. (TSHA) revenue grew by 17.3% year-over-year, from $8.3M to $9.8M in fiscal year 2025.

Is Taysha Gene Therapies, Inc. profitable?

No, Taysha Gene Therapies, Inc. (TSHA) reported a net income of -$109.0M in fiscal year 2025, with a net profit margin of -1115.3%.

What is Taysha Gene Therapies, Inc.'s EBITDA?

Taysha Gene Therapies, Inc. (TSHA) had EBITDA of -$109.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Taysha Gene Therapies, Inc.'s operating margin?

Taysha Gene Therapies, Inc. (TSHA) had an operating margin of -1130.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Taysha Gene Therapies, Inc.'s net profit margin?

Taysha Gene Therapies, Inc. (TSHA) had a net profit margin of -1115.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Taysha Gene Therapies, Inc.'s free cash flow?

Taysha Gene Therapies, Inc. (TSHA) generated -$93.8M in free cash flow during fiscal year 2025. This represents a -15.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Taysha Gene Therapies, Inc.'s operating cash flow?

Taysha Gene Therapies, Inc. (TSHA) generated -$93.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Taysha Gene Therapies, Inc.'s capital expenditures?

Taysha Gene Therapies, Inc. (TSHA) invested $738K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Taysha Gene Therapies, Inc. spend on research and development?

Taysha Gene Therapies, Inc. (TSHA) invested $86.4M in research and development during fiscal year 2025.

How many shares does Taysha Gene Therapies, Inc. have outstanding?

Taysha Gene Therapies, Inc. (TSHA) had 287M shares outstanding as of fiscal year 2025.

Are Taysha Gene Therapies, Inc.'s earnings high quality?

Taysha Gene Therapies, Inc. (TSHA) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Taysha Gene Therapies, Inc. cover its interest payments?

Taysha Gene Therapies, Inc. (TSHA) has an interest coverage ratio of -1753.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.